Inside USP: Characterization of Heparin Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: Characterization of Heparin Products
USP workshop participants support new methods to safeguard heparin products but desire international harmonization. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 10

Continuing to help ensure the identity, purity, and quality of heparin, the US Pharmacopeial Convention (USP) has revised written and physical standards for the widely used blood thinner. In February 2009, USP released updated heparin standards at the request of the US Food and Drug Administration in response to the 2008 public health crisis in which many patients died as a result of adulterated heparin. A second phase of heparin monograph revisions is reflected in the newly posted standards (1). These developments and new analytical characterization tools for heparin were discussed by scientists and regulators at the Third International Heparin Workshop held at USP headquarters in Rockville, Maryland, July 27–28, 2009 (2).

The workshop, cosponsored by USP, the British National Institute of Biological Standards and Control (NIBSC), and the European Directorate for the Quality of Medicines (EDQM), reflected the global nature of both the problem of adulteration and the resources available to combat it. Attendees came from more than 17 countries. Workshop deliberations focused on safeguarding heparin supply, pharmacopeial updates, and progress on biosimilar low-molecular-weight heparins (LMWHs).

Unfractionated heparin

In early 2008, FDA confirmed reports of adverse health events associated with the use of heparin that had been contaminated with oversulfated chondroitin sulfate (OSCS) originating in China (3, 4). In June 2008, USP responded to the heparin crisis by revising its heparin sodium and heparin calcium monographs. Stage-1 monograph revision incorporated FDA's analytical methods for the identification of OSCS in heparin: proton nuclear magnetic resonance spectroscopy (1H NMR) and capillary electrophoresis (CE). Other pharmacopeias followed suit.

Although this short-term measure prevented contaminated heparin from entering the supply chain, USP and stakeholders realized that a thorough modernization of the existing monographs would be needed to ensure the continuing quality of heparin. USP has since undertaken a second stage of revisions to the heparin sodium monograph, adding new identification, potency, and impurity tests that better control the quality of heparin active pharmaceutical ingredient (API). The European Pharmacopoeia (EP) and Japanese Pharmacopoeia (JP) also are taking a stepwise approach to revising their heparin monographs.

LMWHs


Table I: Stage-2 revisions of heparin monographs from world pharmacopeias.
LMWHs are defined as heparin salts that have an average molecular weight of < 8000 Da and for which at least 60% of all chains have a molecular weight of < 8000 Da. LMWHs are prepared from unfractionated heparin (UFH) by various chemical or enzymatic depolymerization processes. Thus, the starting material of LMWHs is of biological origin, and the manufacturing process defines the characteristics of the drug substance. Because the manufacturing process does not necessarily remove all impurities present in UFH, manufacturers should ensure that the starting material complies with the latest regulatory requirements.

Several licensed LMWHs differ in their source material, manufacturing process, pharmacokinetic/pharmacodynamic properties, and therapeutic indications. The development of biosimilar LMWH products has increased globally during the past decade. In anticipation of the arrival of more biosimilar LMWHs in the near future, workshop participants discussed the regulatory framework for follow-on biologic products. Additional topics included regulatory issues (e.g., immunogenicity) and analytical tools aimed at demonstrating comparability to licensed products.

Challenges of heparin characterization

Heparin is structurally the most complex member of the glycosaminoglycan (GAG) family of polysaccharides, which also includes chondroitin sulfate, dermatan sulfate, and keratin sulfate. Commercially available heparin in the US is derived mostly from porcine intestinal mucosa. Selectivity and yield emphasis in the purification steps affect the impurity profile of the resulting API with regard to common impurities such as dermatan sulfate and residual solvents. Because the different GAGs coexist in their natural sources, it is not uncommon to obtain GAG preparations contaminated with a structurally similar polysaccharide.

Because of this complex milieu, the challenges are to sufficiently quantify process impurities and naturally occurring impurities that are not cleared by the purification steps and to concurrently detect any potential contaminants intentionally added to heparin. Workshop partcipants agreed that the quality of crude heparin can only be achieved by complete traceability and good manufacturing practices (GMPs) throughout the manufacturing life cycle and by supplier qualification.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here